Leucoencephalopathy, transverse myelopathy, and peripheral neuropathy in association with glutamic acid decarboxylase-65 (GAD) antibodies in children with cancer

Davonna S. Ledet, Rupert Handgretinger, Tulio Bertorini, Gregory A. Hale, Raul C. Ribeiro, Raja B. Khan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Neurologic toxicity may occur as a direct effect of cancer and its therapy or indirectly because of a dysfunctional immune system. The authors report the development of axonal neuropathy, myelopathy, and leucoencephalopathy associated with glutamic acid decarboxylase-65 (GAD) antibodies in 4 children with progressive cancer who were heavily pretreated. Three patients with refractory leukemia and 1 with Ewing sarcoma developed paraplegia with sensory level and dorsal column dysfunction. Three developed leucoencephalopathy and 1 died of neurologic disease. All had high serum titers of GAD antibodies during the progressive phase of the illness, and the antibody levels returned to normal with the stability of the neurologic disease. Three survivors are showing gradual recovery. This syndrome of central and peripheral nervous system toxicity may have resulted from chemotherapy toxicity or from immune dysfunction, as suggested by the high GAD antibody titers.

Original languageEnglish (US)
Pages (from-to)1357-1362
Number of pages6
JournalJournal of Child Neurology
Volume23
Issue number11
DOIs
StatePublished - Oct 30 2008

Fingerprint

Leukoencephalopathies
Glutamate Decarboxylase
Spinal Cord Diseases
Peripheral Nervous System Diseases
Antibodies
Nervous System Diseases
Neoplasms
Ewing's Sarcoma
Paraplegia
Peripheral Nervous System
Nervous System
Survivors
Immune System
Leukemia
Central Nervous System
Drug Therapy
Serum
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Leucoencephalopathy, transverse myelopathy, and peripheral neuropathy in association with glutamic acid decarboxylase-65 (GAD) antibodies in children with cancer. / Ledet, Davonna S.; Handgretinger, Rupert; Bertorini, Tulio; Hale, Gregory A.; Ribeiro, Raul C.; Khan, Raja B.

In: Journal of Child Neurology, Vol. 23, No. 11, 30.10.2008, p. 1357-1362.

Research output: Contribution to journalArticle

Ledet, Davonna S. ; Handgretinger, Rupert ; Bertorini, Tulio ; Hale, Gregory A. ; Ribeiro, Raul C. ; Khan, Raja B. / Leucoencephalopathy, transverse myelopathy, and peripheral neuropathy in association with glutamic acid decarboxylase-65 (GAD) antibodies in children with cancer. In: Journal of Child Neurology. 2008 ; Vol. 23, No. 11. pp. 1357-1362.
@article{31c93890cade4908909e360df499674f,
title = "Leucoencephalopathy, transverse myelopathy, and peripheral neuropathy in association with glutamic acid decarboxylase-65 (GAD) antibodies in children with cancer",
abstract = "Neurologic toxicity may occur as a direct effect of cancer and its therapy or indirectly because of a dysfunctional immune system. The authors report the development of axonal neuropathy, myelopathy, and leucoencephalopathy associated with glutamic acid decarboxylase-65 (GAD) antibodies in 4 children with progressive cancer who were heavily pretreated. Three patients with refractory leukemia and 1 with Ewing sarcoma developed paraplegia with sensory level and dorsal column dysfunction. Three developed leucoencephalopathy and 1 died of neurologic disease. All had high serum titers of GAD antibodies during the progressive phase of the illness, and the antibody levels returned to normal with the stability of the neurologic disease. Three survivors are showing gradual recovery. This syndrome of central and peripheral nervous system toxicity may have resulted from chemotherapy toxicity or from immune dysfunction, as suggested by the high GAD antibody titers.",
author = "Ledet, {Davonna S.} and Rupert Handgretinger and Tulio Bertorini and Hale, {Gregory A.} and Ribeiro, {Raul C.} and Khan, {Raja B.}",
year = "2008",
month = "10",
day = "30",
doi = "10.1177/0883073808315617",
language = "English (US)",
volume = "23",
pages = "1357--1362",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Leucoencephalopathy, transverse myelopathy, and peripheral neuropathy in association with glutamic acid decarboxylase-65 (GAD) antibodies in children with cancer

AU - Ledet, Davonna S.

AU - Handgretinger, Rupert

AU - Bertorini, Tulio

AU - Hale, Gregory A.

AU - Ribeiro, Raul C.

AU - Khan, Raja B.

PY - 2008/10/30

Y1 - 2008/10/30

N2 - Neurologic toxicity may occur as a direct effect of cancer and its therapy or indirectly because of a dysfunctional immune system. The authors report the development of axonal neuropathy, myelopathy, and leucoencephalopathy associated with glutamic acid decarboxylase-65 (GAD) antibodies in 4 children with progressive cancer who were heavily pretreated. Three patients with refractory leukemia and 1 with Ewing sarcoma developed paraplegia with sensory level and dorsal column dysfunction. Three developed leucoencephalopathy and 1 died of neurologic disease. All had high serum titers of GAD antibodies during the progressive phase of the illness, and the antibody levels returned to normal with the stability of the neurologic disease. Three survivors are showing gradual recovery. This syndrome of central and peripheral nervous system toxicity may have resulted from chemotherapy toxicity or from immune dysfunction, as suggested by the high GAD antibody titers.

AB - Neurologic toxicity may occur as a direct effect of cancer and its therapy or indirectly because of a dysfunctional immune system. The authors report the development of axonal neuropathy, myelopathy, and leucoencephalopathy associated with glutamic acid decarboxylase-65 (GAD) antibodies in 4 children with progressive cancer who were heavily pretreated. Three patients with refractory leukemia and 1 with Ewing sarcoma developed paraplegia with sensory level and dorsal column dysfunction. Three developed leucoencephalopathy and 1 died of neurologic disease. All had high serum titers of GAD antibodies during the progressive phase of the illness, and the antibody levels returned to normal with the stability of the neurologic disease. Three survivors are showing gradual recovery. This syndrome of central and peripheral nervous system toxicity may have resulted from chemotherapy toxicity or from immune dysfunction, as suggested by the high GAD antibody titers.

UR - http://www.scopus.com/inward/record.url?scp=54549086879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54549086879&partnerID=8YFLogxK

U2 - 10.1177/0883073808315617

DO - 10.1177/0883073808315617

M3 - Article

VL - 23

SP - 1357

EP - 1362

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 11

ER -